Loading
Ubix Therapeutics is a Korean company making medicines that make cancer cells break down a target protein rather than just block it. Its lead drug destroys BTK, a protein that drives B-cell blood cancers, including forms resistant to current BTK inhibitors.
Ubix Therapeutics, Inc., based in Songpa-gu, Seoul, develops targeted protein degraders it calls Degraducers. Its lead programme UBX-303-1 (registered as UBX-303061) degrades Bruton's tyrosine kinase (BTK) and, according to the company, showed antitumour activity in preclinical models with wild-type BTK and the C481S resistance mutation; UBX-106 and UBX-306 are undisclosed immuno-oncology programmes. In March 2026 the company withdrew its application for preliminary review of a KOSDAQ listing, saying it would reapply after clinical results and licensing progress. Its first registered cancer trial, NCT06590961, a phase 1a/1b dose-escalation and expansion study of UBX-303061 in relapsed or refractory B-cell malignancies at sites in the United States, Poland and Korea, was posted on ClinicalTrials.gov in September 2024.
Shares BTK (Bruton tyrosine kinase), Non-Hodgkin lymphoma (all types).
Shares PROTACs & molecular glues (targeted protein degradation), Non-Hodgkin lymphoma (all types).
Shares BTK (Bruton tyrosine kinase), PROTACs & molecular glues (targeted protein degradation), Chronic lymphocytic leukaemia.
Shares PROTACs & molecular glues (targeted protein degradation), Chronic lymphocytic leukaemia.
Shares PROTACs & molecular glues (targeted protein degradation), Non-Hodgkin lymphoma (all types).
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
Shares PROTACs & molecular glues (targeted protein degradation), Non-Hodgkin lymphoma (all types).
Shares BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/